Junwei Sun
Founder
VintaBio
VintaBio provides viral vector manufacturing services using a proprietary cell line and transfection method that produces high-yield adeno-associated virus (AAV) vectors for gene therapy applications. The company addresses the need for cost-effective and efficient production processes to accelerate the development of gene therapies for patients in need.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$64MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Shangzhen Zhou
Founder
Product
Problem
The development of gene therapies is often hindered by the high cost and limited availability of viral vector manufacturing, specifically adeno-associated virus (AAV) vectors. Traditional production methods struggle to achieve the yields necessary for dose-demanding indications, creating bottlenecks in research, toxicology studies, and clinical trials. This scarcity and expense ultimately delay the delivery of potentially life-saving treatments to patients.
Solution
VintaBio offers viral vector manufacturing services focused on producing high-yield AAV vectors for gene therapy applications. Their proprietary cell line and transfection method significantly increase vector production, resulting in more vector per dollar. This platform is designed to support clients through all stages of development, from research-grade vector material to toxicology and cGMP-grade material. By providing a cost-effective and efficient manufacturing solution, VintaBio aims to accelerate the development and accessibility of gene therapies.
Target Audience
VintaBio's primary customers are gene therapy developers, researchers, and pharmaceutical companies requiring AAV vector manufacturing services for preclinical research, toxicology studies, and clinical trials.
Features
- Proprietary cell line and transfection method for high AAV vector yields
- Production of 1E17 total vg, suitable for high-dose applications
- Services include research-use-only (RUO), toxicology, and cGMP-grade vector manufacturing
- Integrated supply chain and standardized documentation for GMP readiness
- Turn-key solution covering the entire viral vector manufacturing process, from cell banking to drug product